Lung Cancer Diagnostics

Global Lung Cancer Diagnostics Market to Reach US$4.7 Billion by 2030

The global market for Lung Cancer Diagnostics estimated at US$3.0 Billion in the year 2024, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Imaging Tests, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Sputum Cytology segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$762.0 Million While China is Forecast to Grow at 11.3% CAGR

The Lung Cancer Diagnostics market in the U.S. is estimated at US$762.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Lung Cancer Diagnostics Market - Key Trends & Drivers Summarized

What Innovations Are Shaping Lung Cancer Diagnostics?

The lung cancer diagnostics market has witnessed remarkable innovation in recent years, propelled by advancements in medical technology and a deeper understanding of the disease’s molecular biology. Cutting-edge tools such as liquid biopsies, next-generation sequencing (NGS), and AI-powered imaging solutions are reshaping how lung cancer is identified and monitored. Liquid biopsies, which analyze biomarkers in blood, offer a minimally invasive alternative to traditional tissue biopsies, making diagnostics safer and more patient-friendly. NGS has enabled detailed genetic profiling of tumors, allowing for personalized treatment plans that target specific genetic mutations. Additionally, artificial intelligence has become a game-changer, significantly improving the speed and accuracy of diagnostics by analyzing complex imaging data. These innovations are collectively enhancing early detection rates and enabling more effective treatments.

How Is Precision Medicine Transforming The Landscape?

Precision medicine has brought a paradigm shift to the lung cancer diagnostics market by enabling targeted therapies based on individual patient profiles. Advances in biomarker research, such as identifying EGFR mutations and ALK rearrangements, have made targeted diagnostics an essential part of treatment planning. Companion diagnostics are increasingly paired with specific therapies to identify patients likely to benefit from a given treatment. For instance, PD-L1 testing has become critical for immunotherapy decisions. These diagnostic tools are not only enhancing patient outcomes but also reducing healthcare costs by ensuring appropriate treatment regimens are chosen from the start. With pharmaceutical companies heavily investing in research and development, the integration of precision diagnostics into treatment protocols is expected to accelerate further.

Why Are Emerging Economies Driving Market Growth?

While developed regions like North America and Europe dominate the lung cancer diagnostics market due to robust healthcare infrastructure and advanced research capabilities, emerging economies are quickly becoming key players. Rising pollution levels, increasing tobacco consumption, and growing awareness of early cancer detection are fueling demand in countries like China, India, and Brazil. Governments and private organizations are also investing in healthcare infrastructure to improve accessibility and affordability of diagnostics. Telemedicine platforms and mobile diagnostic units are playing a pivotal role in rural outreach, bridging the gap between urban medical hubs and underserved areas. The expanding middle class in these regions, coupled with increased healthcare expenditure, is further driving the adoption of advanced diagnostic technologies.

What Is Driving Growth in the Lung Cancer Diagnostics Market?

The growth in the lung cancer diagnostics market is driven by several factors, including technological advancements, shifting consumer preferences, and evolving clinical practices. Technological breakthroughs, such as AI integration in imaging and the development of highly sensitive liquid biopsy techniques, are transforming how lung cancer is detected and monitored. The increasing focus on early detection, spurred by growing awareness campaigns, is encouraging more individuals to undergo screening, especially in high-risk populations. Furthermore, the rising prevalence of lung cancer due to environmental and lifestyle factors like air pollution and smoking is expanding the demand for diagnostic services. The adoption of precision diagnostics in conjunction with personalized therapies is also fueling market growth, as pharmaceutical collaborations with diagnostic companies yield better-targeted solutions. Finally, expanding access to healthcare services in emerging markets and the growing emphasis on value-based care are creating a fertile environment for further market expansion.

SCOPE OF STUDY:

The report analyzes the Lung Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Test (Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy, and Other Tests); Type (Non-Small-Cell Lung Cancer (NSCLC), and Small-Cell Lung Cancer (SCLC); and End-Use (Hospital Laboratories, Cancer Research Institutes, and Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Myriad Genetics, Inc.
• F. Hoffmann-La Roche AG
• Biocartis NV
• Epigenomics AG
• Biodesix, Inc.
• Exosome Diagnostics, Inc.
• Admera Health
• Dr Lal PathLabs Ltd.
• Guardant Health, Inc.
• Oncimmune Holding PLC
• Blueprint Genetics OY
• CellMax Life, Inc.
• Circulogene
• BGI Genomics Co Ltd.
• Inivata Ltd.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more